RS1 | Jotup

Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Retrieved on:

Wednesday, March 13, 2024

Gene expression, Safety, Patient, Data, MD, Male, Clinical trial, Therapy, Paratriathlon, RS1, Pharmaceutical industry

ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.

Key Points:

ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.
ATSN-201 was well tolerated in all three XLRS patients in the first cohort and no serious adverse events were reported.
The Data and Safety Monitoring Board recommended proceeding with the second cohort, in which patients will receive the next dose level of ATSN-201.
"We are encouraged by the excellent safety observed with the low dose of ATSN-201 in the LIGHTHOUSE study, which represents the first clinical utilization of AAV.SPR.

Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis

Retrieved on:

Monday, August 28, 2023

DURHAM, N.C., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.

Key Points:

ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the surgical risks of foveal detachment.
“Dosing the first patient in the LIGHTHOUSE study marks a significant milestone for Atsena and the XLRS community,” said Kenji Fujita, MD, Chief Medical Officer of Atsena Therapeutics.
“We are excited to be utilizing AAV.SPR in the clinic, as it has the potential to revolutionize the treatment of XLRS, as well as other inherited retinal disorders.
Spreading laterally beyond the subretinal injection site, AAV.SPR facilitates the safe delivery of RS1 to photoreceptors in the central retina/fovea.

OKdo Selected as Micro:bit Educational Foundation Global Manufacturer and Distributor

Retrieved on:

Monday, June 19, 2023

LONDON, June 19, 2023 /PRNewswire/ -- OKdo, part of the RS Group, is pleased to announce its selection as one of Micro:bit Educational Foundation's leading global manufacturers and distributors. Additionally, this partnership will help foster a new generation of innovators, improving children's computational thinking and unlocking their creative potential.

Key Points:

As a trusted partner, OKdo is committed to supporting The Foundation's mission by ensuring the seamless production and distribution of micro:bits worldwide.
With its expertise, extensive global network and marketing engine in the education sector, OKdo will play a pivotal role in driving educational initiatives and expanding access to micro:bit technology to a new level.
Having already impacted the lives of 39 million children and distributed over 7.5 million devices since its inception in 2016, the Micro:bit Educational Foundation provides quality educational resources to schools and children globally.
OKdo is a global technology company from RS Group plc which is disrupting single board computer (SBC) and IoT segments.

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on:

Tuesday, May 16, 2023

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.

Key Points:

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.
Cre-mediated recombination of ABCA4 was confirmed by mRNA sequencing of RNA from transfected HEK293 cells and AAV-dosed animals.
RS1 expression was associated with improvement in cone photoreceptor density and increased thickness of the photoreceptor outer nuclear layer.
Following intravitreal injection in wild type mice, variants 1 and 7 showed robust protein expression.

Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

Retrieved on:

Monday, May 1, 2023

Male, Research, Paratriathlon, Gene expression, Doctor of Philosophy, Intravitreal administration, Investigational New Drug, Patient, Vivisection, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Medical device, RS1

DURHAM, N.C., May 01, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company’s novel spreading capsids, AAV.SPR, to overcome the challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

Key Points:

ATSN-201 leverages one of the company’s novel spreading capsids, AAV.SPR, to overcome the challenges associated with intravitreally delivered AAVs in the treatment of XLRS.
“Intravitreally delivered AAVs have limitations, as they do not drive sufficient gene expression in photoreceptors to confer therapy and can lead to vision-compromising inflammation,” said Shannon Boye, PhD, Founder and Director of Atsena Therapeutics.
“AAV.SPR is well-suited for use in XLRS as it can drive therapeutic levels of gene expression in photoreceptors while avoiding the surgical risks of foveal detachment, which is important because XLRS patients have fragile retinas due to the presence of schisis lesions.
Building on decades of research, we’re excited to progress our novel gene therapy for patients with XLRS who currently lack an approved treatment option.”
“With the FDA’s clearance of the IND application for ATSN-201, we’re preparing to advance our first program utilizing AAV.SPR into the clinic for the treatment of XLRS in mid-2023,” said Kenji Fujita, Chief Medical Officer of Atsena Therapeutics.

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

Retrieved on:

Tuesday, March 14, 2023

NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from its ophthalmology program. Abeona’s preclinical programs are investigating the use of novel adeno-associated virus (AAV) capsids in therapies for serious genetic eye diseases.

Key Points:

Abeona’s preclinical programs are investigating the use of novel adeno-associated virus (AAV) capsids in therapies for serious genetic eye diseases.
“We are excited by the broad potential for treating serious eye diseases with new AAV-based therapies using novel AAV capsids from our in-licensed AIM™ capsid library and internal research,” said Brian Kevany, Ph.D., Chief Technical Officer and Head of Research at Abeona.
In May 2021 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Abeona reported preclinical data demonstrating the ability of the dual AAV vector system to produce full length ABCA4 protein in cell culture.
Initial efficacy results suggest an improvement in retinal signaling to the brain, and improved visual acuity in treated mutant mice.

Essex County Schools of Technology Partner with the One10Ten Foundation to Accelerate Inclusion, Advocacy, and Access to the World of Motorsports and Beyond

Retrieved on:

Tuesday, January 24, 2023

Technical, Daytona International Speedway, Student, RS1, Partnership, Michelin, Curriculum, Mentorship, Morris County School of Technology, Essex County Schools of Technology, Nursing, Adult

The students will interact with top drivers, pit crews, technical personnel, and team owners.

Key Points:

The students will interact with top drivers, pit crews, technical personnel, and team owners.
The exposure will not only open their eyes to the exciting opportunities in driving, but the broad world of professionals who support the motorsports industry.
This is the beginning of a program designed to familiarize students from underrepresented communities with the vast array of career opportunities available through the world of motorsports.
"We are extremely excited to be partnering with the One10Ten Foundation and the high caliber corporate partners involved to enable young adults to flourish," said Dolan.

Allied Electronics & Automation Offers the Largest Selection of Industrial Control Solutions in North America

Retrieved on:

Monday, January 23, 2023

RS Group, RS, Automation, RS1, RS Group plc, LSE, London Stock Exchange, London, Social media, ICS, Industrial control system, Asset management, Online shopping

FORT WORTH, Texas, Jan. 23, 2023 /PRNewswire/ -- Allied Electronics & Automation, a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, is the largest authorized distributor of industrial control equipment in North America, offering well more than 197,000 products optimized for industrial control systems.

Key Points:

FORT WORTH, Texas, Jan. 23, 2023 /PRNewswire/ -- Allied Electronics & Automation , a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, is the largest authorized distributor of industrial control equipment in North America, offering well more than 197,000 products optimized for industrial control systems.
Allied offers well more than 197,000 industrial control products optimized for ICS applications in multiple markets.
For example, Allied offers cable entry and exit solutions for industrial control cabinets, including rectangular connectors from ILME and cable gland adapters from Mencom .
For assistance identifying and deploying industrial control solutions, please contact your local Allied representative at 1.866.433.5722 or reach out to Allied's technical support team .

Allied Electronics & Automation Announces Ready-to-Ship Solutions for Medical Industry Applications

Retrieved on:

Wednesday, January 4, 2023

FORT WORTH, Texas, Jan. 4, 2023 /PRNewswire/ -- Allied Electronics & Automation, a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, announces ready-to-ship solutions for medical industry applications from ABB Robotics, Bürkert Fluid Control Systems, Keystone Technologies, and MicroCare.

Key Points:

FORT WORTH, Texas, Jan. 4, 2023 /PRNewswire/ -- Allied Electronics & Automation , a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, announces ready-to-ship solutions for medical industry applications from ABB Robotics, Bürkert Fluid Control Systems, Keystone Technologies, and MicroCare.
Medical industry applications include improving assembly and production efficiencies and assisting with lab testing procedures.
For assistance identifying and deploying products engineered for use in medical industry applications, please contact your local Allied representative at 1.866.433.5722 or reach out to Allied's technical support team .
For more information about Allied Electronics & Automation, please visit www.alliedelec.com/ or connect with us via social media on Facebook , Twitter , and LinkedIn .

Allied Electronics & Automation Adds 12 New Suppliers to Better Serve Industrial and Commercial Customers

Retrieved on:

Monday, December 12, 2022

FORT WORTH, Texas, Dec. 12, 2022 /PRNewswire/ -- Allied Electronics & Automation, a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, expanded its extensive portfolio of more than 3.5 million products from more than 650 trusted suppliers with the addition of more than 1,400 ready-to-ship solutions from 12 new suppliers to better serve its industrial and commercial customers.

Key Points:

FORT WORTH, Texas, Dec. 12, 2022 /PRNewswire/ -- Allied Electronics & Automation , a trading brand of RS Group plc (LSE: RS1), a global omni-channel provider of product and service solutions, expanded its extensive portfolio of more than 3.5 million products from more than 650 trusted suppliers with the addition of more than 1,400 ready-to-ship solutions from 12 new suppliers to better serve its industrial and commercial customers.
Allied expanded its connectivity portfolio with the addition of more than 300 ready-to-ship products from HUBER+SUHNER and Mencom Corporation.
Allied currently offers more than 450 ready-to-ship Philips lighting solutions optimized for use in homes, commercial businesses, and industrial operations.
For more information about Allied Electronics & Automation, please visit www.alliedelec.com/ or connect with us via social media on Facebook , Twitter , and LinkedIn .